Proactive Investors - Run By Investors For Investors

Concepta jumps as it inks deal to sell myLotus in Boots' chemists

The healthcare firm said the agreement with Walgreens Boots Alliance would allow it to supply Boots stores in the UK as well as other partners across EU markets
Boots sign
The Boots deal forms a part of Concepta's plan to roll out myLotus across the EU

Concepta PLC (LON:CPT) shares jumped in mid-morning trading Tuesday after it inked an agreement to supply its myLotus fertility testing kit to high street chemist Boots.

The healthcare firm said the agreement with Walgreens Boots Alliance Inc (NASDAQ:WBA),  which owns both Boots and US pharmacy chain Walgreens, would allow it to supply Boots stores in the UK as well as other WBA partners across EU markets that use the CE-Mark, a quality standard for the European Economic Area that myLotus achieved last October.

READ: Concepta hails successful UK launch of myLotus fertility testing product

myLotus is a self-testing kit that allows women to measure their fertility levels and determine when they are most likely to become pregnant naturally, offering an alternative to expensive treatments like in-vitro fertilisation (IVF).

Matthew Walls, chairman of Concepta, said the firm was “delighted to work with such a respected British high-street brand” and was now preparing its roll-out plans for the EU market.

Investor hails deal as “validation” of myLotus appeal

In a separate announcement, Mercia Technologies PLC (LON:MERC), an investment group that owns an 18.2% stake in Concepta, hailed the deal as “validation” that the myLotus product had “significant commercial appeal”.

“This new partnership will play a pivotal role in myLotus being more widely available across the UK and overseas", said Peter Dines, Mercia’s chief operating officer who is also a non-executive director of Concepta.

Shares were up 4% at 3.95p.

--Adds share price--

View full CPT profile View Profile

Concepta Timeline

Related Articles

April 02 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has made significant progress since it started trading on NEX.
Weight loss
January 07 2019
A deal with Indian firm Zeon Lifesciences in January is the ninth deal the firm has secured for the weight loss product
man pointing to brain
April 25 2019
Brain Scientific’s EEG technology is far cheaper and less bulky than a traditional EEG system, but provides EEG tracings of the same quality

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use